FCGRT and autoimmune disease: Efgartigimod alfa (also known as efgartigimod alfa-fcab in the USA) represents the first-in-class FcRn antagonist developed by argenx for the treatment of autoimmune diseases mediated by pathogenic IgG autoantibodies.